Similar to how obese patients respond better to PD-1 inhibitor therapy, obese RCC patients tend to respond better and have longer OS when treated with anti-VEGF therapies such as sunitinib, sorafenib, and bevacizumab, and axitinib [95,96]. The gene discussed is VEGFA; the disease is renal cell carcinoma.